文献速递鼻科头颈外科

嗜酸性肉芽肿性多血管炎中的慢性鼻窦炎与鼻息肉:范围综述

Chronic Rhinosinusitis and Nasal Polyps in Eosinophilic Granulomatosis With Polyangiitis: A Scoping Review.
PubMed 文献 · Int Forum Allergy Rhinol · 2026-07-13

本范围综述检索MEDLINE、Embase等数据库至2025年6月4日,纳入109项研究(分析88项,含1087例CRS合并EGPA患者)。CRSwNP占69.3%,CRSsNP占30.7%,CRS起病至EGPA诊断中位时间66个月。系统激素、免疫抑制剂和生物制剂使用率分别为91%、86.6%和58.9%,完全缓解率药物组67.9%、手术联合药物组18.2%。

要点

  • EGPA相关CRS以CRSwNP为主(69.3%),CRSsNP占30.7%。
  • CRS起病至EGPA诊断中位延迟66个月,需警惕鼻窦表现先于系统血管炎。
  • 生物制剂使用率58.9%,以美泊利珠单抗为主(73.3%)。

核心结论

  • CRSwNP是EGPA最主要的鼻窦表型,管理正转向靶向生物制剂。
  • 需要标准化结局报告和前瞻性对照研究以优化管理并减少诊断延迟。

研究设计与样本

  • 范围综述,检索MEDLINE、Embase、CENTRAL、CINAHL和Web of Science至2025年6月4日。
  • 纳入试验、队列、病例系列和叙述性综述,排除无翻译的非英语研究和无原始数据的文章。
  • 最终纳入109项研究,其中88项(74篇全文和14篇摘要)进入分析。

主要发现

  • 分析研究共纳入1087例CRS合并EGPA患者,中位年龄53岁(范围14.5-75,n=154),男性189例(48.5%,n=390)。
  • CRSwNP和CRSsNP分别发生于753例(69.3%)和334例(30.7%)患者。
  • CRS起病至EGPA诊断的中位时间为66个月(范围1-120,n=35)。
  • 857例患者中,EGPA分类采用ACR 1990标准者占51.7%,ACR/EULAR 2022标准者占2.7%,联合框架者占45.6%。
  • 诊断方式包括鼻窦CT(97.6%)、鼻内镜(94.7%)和鼻窦活检(91.8%),活检证实的血管炎仅3例(1.3%)。

关键数值与推荐

  • 系统激素使用362例(91%,n=398),免疫抑制剂290例(86.6%,n=336),生物制剂154例(58.9%,n=262)。
  • 生物制剂以美泊利珠单抗(73.3%)、度普利尤单抗(23.4%)和贝那利珠单抗(11.7%)为主。
  • 药物治疗后CRS完全缓解106例(67.9%),手术联合药物治疗后完全缓解11例(18.2%)。
  • 接受度普利尤单抗者(n=15)中,SNOT-22平均改善25.2(n=9),6例(83.3%)完全缓解。

临床怎么用

  • 对CRSwNP患者应警惕潜在EGPA,尤其当鼻窦症状先于系统诊断多年出现时。
  • 生物制剂(美泊利珠单抗、贝那利珠单抗)可用于EGPA的系统疾病控制。
  • 鼻窦活检证实血管炎的比例低(1.3%),诊断需结合临床和系统评估。

局限性

  • 纳入研究以队列和病例系列为主,缺乏前瞻性对照研究。
  • 部分分析基于摘要数据,可能存在报告不完整。
  • 各研究EGPA分类标准不一致,影响结果可比性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic rhinosinusitis (CRS) is one of the most common manifestations of eosinophilic granulomatosis with polyangiitis (EGPA), often preceding the diagnosis of systemic vasculitis by several years. The sinonasal presentation of EGPA typically resembles CRS with nasal polyps (CRSwNP), making it clinically indistinguishable from those without EGPA. This overlap frequently contributes to significant diagnostic delays. This scoping review summarizes the prevalence, diagnosis, management, and outcomes of CRSwNP and CRS without nasal polyps (CRSsNP) in EGPA. METHODS: We searched MEDLINE, Embase, CENTRAL, CINAHL, and Web of Science from inception to June 4, 2025, for studies reporting CRS in patients with EGPA. Eligible designs included trials, cohorts, case series, and narrative reviews. Non-English studies without translation and articles without primary data were excluded. Outcomes included CRS prevalence, diagnostic modalities, management strategies, and sinonasal outcomes. This study is registered with the Open Science Framework (DOI: 10.17605/OSF.IO/DA5CK). RESULTS: Eighty-three full-text and 26 abstracts were included, for a total of 109 studies, of which 88 studies (74 full-text and 14 abstracts were included in the analysis). Across the analyzed studies, 1087 patients with CRS and EGPA were included. Median age was 53 years (range: 14.5-75; n = 154), and 189 (48.5%; n = 390) were male. CRSwNP and CRSsNP occurred in 753 (69.3%) and 334 (30.7%) of patients, respectively. The median time from CRS onset to EGPA diagnosis was 66 months (range: 1-120; n = 35). Among 857 patients, EGPA was classified using ACR 1990 criteria (51.7%), ACR/EULAR 2022 (2.7%), and combined frameworks (45.6%). Diagnostic modalities included CT sinus (97.6%), nasal endoscopy (94.7%), and sinus biopsy (91.8%). Biopsy-proven vasculitis was confirmed in three (1.3%) patients. Systemic steroids were used in 362 (91%; n = 398) patients, immunosuppressants in 290 (86.6%; n = 336) patients, and biologics in 154 (58.9%; n = 262) patients, primarily mepolizumab (73.3%), dupilumab (23.4%), and benralizumab (11.7%). Complete CRS remission was achieved in 106 (67.9%) patients following medical therapy and in 11 (18.2%) patients after combined surgical and medical treatment. Among those receiving dupilumab (n = 15), mean SNOT-22 improved by 25.2 (n = 9), with complete remission in six (83.3%) patients. CONCLUSIONS: CRSwNP is the predominant sinonasal phenotype of EGPA. Management is shifting toward targeted biologics with evidence supporting mepolizumab and benralizumab for systemic disease control. Standardized outcome reporting and prospective comparative studies are needed to optimize management and reduce diagnostic delays.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Sharma A, Li AY, Kishibe T, et al. Chronic Rhinosinusitis and Nasal Polyps in Eosinophilic Granulomatosis With Polyangiitis: A Scoping Review. Int Forum Allergy Rhinol. 2026. PMID: 42439219. doi:10.1002/alr.70217

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。